Free Trial

Avantor (AVTR) Stock Forecast & Price Target

$25.54
-0.33 (-1.28%)
(As of 11:07 AM ET)

Avantor - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
3
Buy
12

Based on 15 Wall Street analysts who have issued ratings for Avantor in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 15 analysts, 3 have given a hold rating, and 12 have given a buy rating for AVTR.

Consensus Price Target

$28.00
9.67% Upside
According to the 15 analysts' twelve-month price targets for Avantor, the average price target is $28.00. The highest price target for AVTR is $34.00, while the lowest price target for AVTR is $23.00. The average price target represents a forecasted upside of 9.67% from the current price of $25.54.
Get the Latest News and Ratings for AVTR and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Avantor and its competitors.

Sign Up

AVTR Analyst Ratings Over Time

TypeCurrent Forecast
10/2/23 to 10/1/24
1 Month Ago
9/2/23 to 9/1/24
3 Months Ago
7/4/23 to 7/3/24
1 Year Ago
10/2/22 to 10/2/23
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
12 Buy rating(s)
12 Buy rating(s)
12 Buy rating(s)
9 Buy rating(s)
Hold
3 Hold rating(s)
4 Hold rating(s)
4 Hold rating(s)
4 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$28.00$27.40$26.29$25.93
Forecasted Upside9.67% Upside6.04% Upside25.11% Upside24.38% Upside
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy

AVTR Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

AVTR Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Avantor Stock vs. The Competition

TypeAvantorMedical CompaniesS&P 500
Consensus Rating Score
2.80
2.78
2.50
Consensus RatingModerate BuyModerate BuyHold
Predicted Upside8.23% Upside823.00% Upside6.15% Upside
News Sentiment Rating
Positive News

See Recent AVTR News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
9/26/2024Royal Bank of Canada
4 of 5 stars
 Reiterated RatingOutperform ➝ Outperform$34.00 ➝ $34.00+29.92%
8/27/2024Wells Fargo & Company
3 of 5 stars
B. Couillard
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$30.00+17.14%
7/29/2024Morgan Stanley
3 of 5 stars
 Boost TargetOverweight ➝ Overweight$28.00 ➝ $29.00+10.81%
7/29/2024TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$28.00 ➝ $31.00+18.32%
7/29/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$25.00 ➝ $28.00+7.36%
7/29/2024Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$27.00 ➝ $28.00+9.37%
7/29/2024Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$26.00 ➝ $27.00+5.47%
7/10/2024Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
P. Donnelly
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral$30.00 ➝ $23.00+10.13%
7/2/2024Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform ➝ Outperform$28.00 ➝ $27.00+30.88%
4/18/2024Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetHold ➝ Hold$23.00 ➝ $25.00+2.54%
2/15/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$25.00 ➝ $29.00+18.13%
2/15/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$26.00 ➝ $29.00+18.08%
1/26/2024Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$22.50 ➝ $26.00+18.51%
12/13/2023Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoveragePeer Perform
12/7/2023The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$23.00 ➝ $26.00+23.99%
9/28/2023Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageMarket Perform$22.00+5.90%
7/31/2023William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Larew
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Market Perform
7/30/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy$27.00 ➝ $24.00+12.78%
5/1/2023888
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingMaintains
11/1/2022Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$26.00+30.13%
10/31/2022Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetNeutral$32.00 ➝ $25.00+30.07%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 11:32 AM ET.


AVTR Forecast - Frequently Asked Questions

According to the research reports of 15 Wall Street equities research analysts, the average twelve-month stock price forecast for Avantor is $28.00, with a high forecast of $34.00 and a low forecast of $23.00.

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avantor in the last year. There are currently 3 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" AVTR shares.

According to analysts, Avantor's stock has a predicted upside of 9.63% based on their 12-month stock forecasts.

Over the previous 90 days, Avantor's stock had 1 downgrade by analysts.

Avantor has been rated by research analysts at Barclays, Citigroup, Morgan Stanley, Robert W. Baird, Royal Bank of Canada, Stifel Nicolaus, TD Cowen, and Wells Fargo & Company in the past 90 days.

Analysts like Avantor more than other "medical" companies. The consensus rating score for Avantor is 2.80 while the average consensus rating score for "medical" companies is 2.78. Learn more on how AVTR compares to other companies.


This page (NYSE:AVTR) was last updated on 10/1/2024 by MarketBeat.com Staff
From Our Partners